Skip to main content
. 2022 Aug 18;41(2):233–242. doi: 10.1200/JCO.22.00184

FIG 3.

FIG 3.

(A) EORTC QLQ-C-30 scores at baseline, pre-excision, 6 months, and 12 months after TES. Functioning and global scales were scored from 0 to 100, with higher scores indicating better QoL. Observed/expected sample size was 58/58 at baseline, 53/58 at pre-excision, 37/43 at 6 months after TES, and 23/26 at 12 months after TES. (B) LARS mean total scores at baseline, pre-excision, 6 months, and 12 months after excision. Scores of 0-20 correspond to no LARS, 21-29 to minor LARS, and 30-42 to major LARS. Observed/expected sample size was 58/58 baseline, 50/58 pre-excision, 36/43 at 6 months after TES, and 21/26 at 12 months after TES. (C) FIQL mean scores at baseline, pre-excision, 6 months, and 12 months after excision. FIQL was scored with a range from 1 to 5 with 1 indicating a lower functional status of QoL. Observed/expected sample size was 52/58 at baseline, 52/58 at pre-excision, 37/43 at 6 months after TES, and 23/26 at 12 months after TES. EORTC QLQ-C-30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–C30; FIQL, Fecal Incontinence Quality of Life; LARS, Low Anterior Resection Syndrome; QoL, quality of life; TES, transanal excision surgery.